Pelthos Therapeutics Inc 2026年季度报告

FORM 10-Q (Mark One) For the quarterly period ended March31, 2026 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________to _______________. Commission File Number: 001-41964 Pelthos Therapeutics Inc.(Exact name of registrant as specified in its charter) 86-3335449 (I.R.S. Employer Identification No.) Pelthos Therapeutics Inc.4020 Stirrup Creek Drive, Suite 110Durham, NC 27703(Address of principal executive offices) (Zip Code) (919) 908-2400 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on whichregistered Common Stock, par value $0.0001 pershare Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒ Accelerated filer☐Smaller reporting company☒Emerging growth company☒ If an emerging growth company, indicate by check-mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ The number of shares of the registrant’s common stock outstanding as of May11, 2026 is 3,475,645. PageNumberPART I: FINANCIAL INFORMATION3Item 1. Financial Statements (unaudited)3Condensed Consolidated Balance Sheets3Condensed Consolidated Statements of Operations and Comprehensive Loss4Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit)5Condensed Consolidated Statements of Cash Flows6Notes to Condensed Consolidated Financial Statements8Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations47Item 3. Quantitative and Qualitative Disclosures About Market Risk71Item 4. Controls and Procedures71PART II. OTHER INFORMATION73Item 1. Legal Proceedings73Item 1A. Risk Factors73Item 2. Unregistered Sales of Equity Securities and Use of Proceeds73Item 3. Defaults Upon Senior Securities74Item 4. Mine Safety Disclosures74Item 5. Other Information74Item 6. Exhibits75 SIGNATURES76 PELTHOS THERAPEUTICS INC.CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands, except share and per share amounts) (in thousands, except share and per share amounts) PELTHOS THERAPEUTICS INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSFOR THE THREE MONTHS ENDED MARCH31, 2026 AND 2025(Unaudited) PELTHOS THERAPEUTICS INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSFOR THE THREE MONTHS ENDED MARCH31, 2026 AND 2025 (CONTINUED)(Unaudited)(in thousands, except share and per share amounts) PELTHOS THERAPEUTICS INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)(dollar values in thousands, except per share data) NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS Description of Business Pelthos Therapeutics Inc. (the “Company”) is a bio-pharmaceutical company committed to commercializing innovative, safe, andefficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and DrugAdministration(“FDA”)approved products in its commercial portfolio,in various stages of commercialization,includingZELSUVMI , XEPI , and XEGLYZE .®®® The Company is currently actively promoting one commercial product, ZELSUVMI (berdazimer) topical gel, 10.3% for the treatmentof molluscum contagiosum, which was approved by the FDA in January 2024 and was commercially launched in July 2025.Berdazimer sodium is the active pharmaceutical ingredient (“API”) used in ZELSUVMI and is the backbone of the NITRICIL™platform technology. During the fourth quarter of 2025, the Company acquired the rights to both XEPI and XEGLYZE, for thetreatment of impetigo and head lice, respectively, and is preparing them for future commercialization. The Company leases itsmanufacturing facility, owns and operates the equipment used in the production of